FDA Approves WIDAPLIK — Azurity Pharmaceuticals, Inc.

Azurity Pharmaceuticals secured FDA approval Friday for WIDAPLIK (telmisartan, amlodipine and indapamide), a new oral antihypertensive. This launch strengthens Azurity’s portfolio in the market for fixed-dose combinations and broadens access to treatment options capable of more aggressively lowering blood pressure in patients unresponsive to monotherapy.